In recent years, PLK1 inhibitors have demonstrated notable tumor reduction in highly proliferative CCND1-driven breast cancer bone metastases [13] and improved oxaliplatin resistance levels in patients with advanced colorectal cancer [14]. Here, PLK1 is linked to neoplasm.